Immunogenicity of the Bivalent Oral Cholera Vaccine Shanchol in Haitian Adults With HIV Infection

We evaluated immune responses following bivalent oral cholera vaccination (Shanchol [Shantha Biotechnics]; BivWC) in a cohort of 25 human immunodeficiency virus (HIV)-infected adults in Haiti. Compared with adults without HIV infection, vaccination in HI V-infected individuals resulted in lower vibr...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2015-09, Vol.212 (5), p.779-783
Main Authors: Ivers, Louise, Charles, Richelle C., Hilaire, Isabelle J., Mayo-Smith, Leslie M., Teng, Jessica E., Jerome, J. Gregory, Rychert, Jenna, LaRocque, Regina C., Xu, Peng, Kováč, Pavol, Ryan, Edward T., Qadri, Firdausi, Almazor, Charles P., Franke, Molly F., Harris, Jason B.
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
BACTERIA
Blood Bactericidal Activity
CD4 Lymphocyte Count
Cholera - prevention & control
Cholera Vaccines - administration & dosage
Cholera Vaccines - immunology
Cohort Studies
Female
Haiti
HIV Infections - complications
HIV Infections - immunology
Humans
Immunoglobulin A - blood
Lentivirus
Major and Brief Reports
Male
Microbial Viability
Middle Aged
Retroviridae
Vibrio cholerae
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated immune responses following bivalent oral cholera vaccination (Shanchol [Shantha Biotechnics]; BivWC) in a cohort of 25 human immunodeficiency virus (HIV)-infected adults in Haiti. Compared with adults without HIV infection, vaccination in HI V-infected individuals resulted in lower vibriocidal responses against Vibrio cholerae 01, and there was a positive relationship between the CD4⁺ T-cell count and vibriocidal responses following vaccination. Nevertheless, seroconversion occurred at a rate of 65% against the Ogawa serotype and 74% against the Inaba serotype in adults with HIV infection. These results suggest that the vaccine retains substantial immunogenicity in adults with HIV infection and may benefit this population by protecting against cholera.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiv108